MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT
Sept 15, 2025 | Bruce Sands, MD, MS
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

1. Where are you in your career? (Required.)

IBD Specialist

General GI

Fellow/Trainee

APP

PharmD

Other (please specify)

Question Title

2. What is your community of practice? (Required.)

Academic

Community

Industry

Other (please specify)

Question Title

3. #NewIBDdrugOntheBlock
What’s next in the IL23 story?

#ANTHEM-UC is a phase 2b trial that assessed #Icotrokinra efficacy vs placebo in mod-severe UC

What is the MOA of this drug
🔑mAb = monoclonal antibody
🔑i = inhibitor (Required.)

IL23i mAb IV

IL23i mAb SQ

IL23Receptor-i PO peptide

IL23Receptor-i IV mAb

Question Title

4. #NewIBDdrugsOntheBlock

🔮 Is Dual Targeted Therapy (DTT) in our near future to optimize treatment response in #IBD ?

🔮Which DTT trials are in the works/ happening ? (Required.)

1/DUET-CD & UC: GUS+GOLI

2/VICTRIVA: Vedo + UPA

3/SONIC: IFX + AZA

1/ and 2/

EVALUATION FORM

Question Title

5. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
9. Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD	9. Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Strongly agree	9. Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Agree	9. Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Disagree	9. Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD Strongly disagree

Question Title

6. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree
The educational resources provided to me at the educational activity are useful to my practice	The educational resources provided to me at the educational activity are useful to my practice Strongly agree	The educational resources provided to me at the educational activity are useful to my practice Agree	The educational resources provided to me at the educational activity are useful to my practice Disagree	The educational resources provided to me at the educational activity are useful to my practice Strongly disagree

Question Title

7. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

8. If no, please explain:

Question Title

9. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Awareness of novel therapies and treatment approaches that my patients may benefit from

Understand the role of treat-to-target when utilizing combination therapy strategies

Heightened understanding of clinical trial design and pipeline for new therapeutics in IBD

Useful therapies and appropriate uses

Cutting-edge science in this therapeutic area

Best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Absence of regulatory approval of novel therapies

Insurance, reimbursement or legal issues

Patient adherence/resistance to change

Other (please specify)

Question Title

12. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information. (Required.)

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACTSept 15, 2025 | Bruce Sands, MD, MS ***Post-Survey & Application for CME Credit***

Question Title

* 1. Where are you in your career? (Required.)

Question Title

* 2. What is your community of practice? (Required.)

Question Title

* 3. #NewIBDdrugOntheBlockWhat’s next in the IL23 story?#ANTHEM-UC is a phase 2b trial that assessed #Icotrokinra efficacy vs placebo in mod-severe UC What is the MOA of this drug 🔑mAb = monoclonal antibody 🔑i = inhibitor (Required.)

Question Title

* 4. #NewIBDdrugsOntheBlock 🔮 Is Dual Targeted Therapy (DTT) in our near future to optimize treatment response in #IBD ?🔮Which DTT trials are in the works/ happening ? (Required.)

Question Title

* 5. Upon completion of this activity, I am able to:

Question Title

* 6. Please indicate the extent of your agreement with the following statements:

Question Title

* 7. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 8. If no, please explain:

Question Title

* 9. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 12. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.* (Required.)

Question Title

* 13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT" and claim 1.0 AMA PRA Category 1 CreditTM. (Required.)

MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT
Sept 15, 2025 | Bruce Sands, MD, MS
Post-Survey & Application for CME Credit

1. Where are you in your career? (Required.)

2. What is your community of practice? (Required.)

3. #NewIBDdrugOntheBlock
What’s next in the IL23 story?

#ANTHEM-UC is a phase 2b trial that assessed #Icotrokinra efficacy vs placebo in mod-severe UC

What is the MOA of this drug
🔑mAb = monoclonal antibody
🔑i = inhibitor (Required.)

4. #NewIBDdrugsOntheBlock

🔮 Is Dual Targeted Therapy (DTT) in our near future to optimize treatment response in #IBD ?

🔮Which DTT trials are in the works/ happening ? (Required.)

5. Upon completion of this activity, I am able to:

6. Please indicate the extent of your agreement with the following statements:

7. Overall, was this activity fair, balanced and free from commercial bias?

8. If no, please explain:

9. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

10. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

11. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

12. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information. (Required.)

13. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IBD Trials to Watch: Part 2 ~ IL-23s & ACT" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)